Dedicated to the development and commercialization of oncology products, Poniard Pharmaceuticals is a cancer therapeutics development company. The company s main focus is on the development of picoplatin, a next-generation platinum therapy with improved safety features that is designed to overcome platinum-based chemoresistance. Poniard Pharmaceuticals is studying picoplatin in a Phase II trial in patients with small cell lung cancer. The company is collaborating with Scripps Florida, a division of the Scripps Florida Research Institute, on the discovery of novel, small-molecule, multi-targeted, protein kinase inhibitors as therapeutic agents, including cancer treatments. Poniard Pharmaceuticals maintains its corporate headquarters in South San Francisco, Calif.
Partial Data by Infogroup (c) 2024. All rights reserved.